24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
After a decline last year, the Russian pharmaceutical industry has returned to growth. According to the analytical company RNC Pharma, pharmaceutical manufacturers operating in Russia produced over 630 million packages of finished pharmaceuticals in January–February 2026, representing a 6.7% increase compared to the same period last year. In monetary terms, production volume reached 164.9 billion rubles , an increase of 13.8% compared to January–February 2025.
Analysts also note a shift in market structure. The share of prescription drugs in total production has exceeded 52% in packaged form. Meanwhile, the over-the-counter (OTC) segment continues to shrink: over the past three years, their production has consistently declined, and by the end of 2025, the decline was 7.7%.
Among prescription medications, unbranded oseltamivir, produced by seven Russian companies during the reporting period, demonstrated the most significant growth. Production volume for this product tripled. Among prescription brands, Prevenar, manufactured at the Petrovax facility in Podolsk, led the growth: its production volume also tripled.
In the over-the-counter drug segment, Miramistin, manufactured by Infamed, demonstrated the highest growth in sales at the beginning of 2026. Production volume of this drug increased 43-fold over the year.
An additional indicator of the industry's development was the results of an analysis of the public procurement market. The Cursor analytical platform presented a ranking of full-cycle manufacturers based on the results of 2025. According to the report, by the beginning of 2026, the Russian Ministry of Industry and Trade confirmed full-cycle production for 169 international nonproprietary names. Biocad led the ranking by sales volume, with 48.8 billion rubles, representing 42% of the full-cycle drug market.
The growth in production volumes and the development of the full-cycle drug segment confirm the ongoing strengthening of Russian pharmaceutical capacity, as well as the changing structure of supply on the domestic market.
* Source : GxP News.
